Alloy Therapeutics and CDMO Wheeler Bio formed a nonexclusive, preferred service offering to advance potential new products from discovery to CMC development, GMP manufacturing, and clinical material supply for existing and future ATX-Gx platform users and Alloy Discovery Service partners who also contract Portable CMC™ development services with Wheeler Bio.

Alloy Therapeutics和CDMO Wheeler Bio形成了一项非排他性的首选服务，为现有和未来的ATX Gx平台用户以及也与便携式CMC签订合同的合金发现服务合作伙伴提供潜在的新产品，从发现到CMC开发，GMP制造和临床材料供应™ Wheeler Bio的开发服务。

Aligned with its open collaboration model, Alloy partners are still free to use any CDMO of their choice..

与其开放式合作模式相一致，合金合作伙伴仍可自由使用他们选择的任何CDMO。。

“Following every antibody and bispecific discovery process, CMC becomes the critical path to treating patients. We developed this preferred offering with Wheeler to support Alloy’s partners with the highest quality cell line development and GMP manufacturing process possible,” said Errik Anderson, CEO and founder at Alloy Therapeutics.

“在每个抗体和双特异性发现过程之后，CMC成为治疗患者的关键途径。我们开发了这一首选产品，与Wheeler一起支持合金的合作伙伴，提供最高质量的细胞系开发和GMP制造工艺，”Errik Anderson，首席执行官兼创始人说。在Alloy Therapeutics。

“Alloy is helping to lower the cost of drug development by reducing our partners’ downstream payments dollar-for-dollar on their path to the clinic. Wheeler’s high-quality, predictable, fit-for-purpose approach increases the probability of success and reduces the time to clinic for these drug programs.”.

“合金正在帮助降低药物开发成本，通过减少合作伙伴在临床路径上的下游支付美元/美元，惠勒的高质量，可预测，适合目的的方法增加了成功的可能性并缩短了时间为这些药物计划临床“。

Antibody discovery platforms

抗体发现平台

Alloy provides antibody discovery platforms and services with over 150 partners to date. The company’s ATX-Gx platform is a transgenic mouse strain for fully human antibody discovery.

迄今为止，Alloy为150多个合作伙伴提供抗体发现平台和服务。该公司的ATX Gx平台是用于全人类抗体发现的转基因小鼠品系。

“By closely aligning Alloy’s discovery platform with Wheeler’s development and manufacturing platform, our ecosystem clients benefit immensely by skipping the CDMO RFP process while reducing risk in tech transfers,” said Jesse McCool, CEO and co-founder at Wheeler. “Our bioprocess models are in lockstep with ATX-Gx derived antibodies.”.

Wheeler的首席执行官兼联合创始人Jesse McCool说：“通过将Alloy的发现平台与Wheeler的开发和制造平台紧密结合，我们的生态系统客户可以通过跳过CDMO RFP流程同时降低技术转让风险而获益良多。“我们的生物过程模型与ATX Gx衍生抗体同步。”。

“We are elated to participate as an early adopter of the Alloy-Wheeler partnership to speed our path from discovery to CMC development and first patient dosing,” stated Hemanta Baruah, co-founder and CEO at Aakha Biologics. “Both Alloy and Wheeler are laser focused on meeting our needs as a small biotech startup with specific goals to generate early data to further enable our fundraising efforts.”.

Aakha Biologics的联合创始人兼首席执行官Hemanta Baruah说：“我们很高兴成为Alloy-Wheeler partnership的早期采用者，以加快我们从发现到CMC开发和第一次患者剂量的道路。“作为一家小型生物技术初创企业，Alloy和Wheeler都致力于满足我们的需求，其具体目标是生成早期数据，以进一步实现我们的筹款工作。”。

Antibodies (Immune system)Drug development (Research and development)Good manufacturing practiceSoftwareAlloy TherapeuticsWheeler Bio

抗体（免疫系统）药物开发（研究与开发）Heeler Bio的软件治疗药物的良好生产实践